Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | DRD3 | P35462 | 3/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.82 |
| ▸ | HTR2A | P28223 | 2/20 | 0.82 |
| ▸ | HTR2B | P41595 | 2/20 | 0.82 |
| ▸ | BLM | P54132 | 2/20 | 0.82 |
| ▸ | CNR1 | P21554 | 1/20 | 0.82 |
| ▸ | APEX1 | P27695 | 1/20 | 0.82 |
| ▸ | PDE4A | P27815 | 1/20 | 0.82 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.82 |
| ▸ | DRD2 | P14416 | 2/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | CYP2J2 | P51589 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.74 |
| ▸ | GMNN | O75496 | 1/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1969969 | 1.00 | HRH1 (0.82) | HRH1LMNADRD3KCNH2HTR2A | |
| SCHEMBL5603264 | 1.00 | HRH1 (0.82) | HRH1LMNADRD3KCNH2HTR2A | |
| SCHEMBL6826935 | 0.93 | LMNA (0.71) | HRH1LMNADRD3KCNH2HTR2A | |
| SCHEMBL25883699 | 0.93 | HRH1 (0.79) | HRH1LMNADRD3KCNH2HTR2A | |
| SCHEMBL2454926 | 0.92 | HRH1 (0.69) | HRH1LMNADRD3KCNH2HTR2A | |
| SCHEMBL18609222 | 0.91 | HRH1 (0.68) | HRH1LMNADRD3KCNH2HTR2A | |
| SCHEMBL5999820 | 0.91 | HRH1 (0.79) | HRH1LMNADRD3KCNH2HTR2A | |
| SCHEMBL5999809 | 0.91 | HRH1 (0.79) | HRH1LMNADRD3KCNH2HTR2A | |
| SCHEMBL1968090 | 0.91 | HRH1 (0.79) | HRH1LMNADRD3KCNH2HTR2A | |
| Fexofenadine SCHEMBL1561082 | 0.90 | HRH1 (1.00) | HRH1LMNADRD3KCNH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0701443-A1 | TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS | SEPRACOR, INC. (US) | 1996-03-20 | — | — | EP | claimed |
| WO-1994003170-A1 | TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS | SEPRACOR INC. (US) | 1994-02-17 | — | — | WO | claimed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-8404715-B2 | Methods and compositions using racemic, (R)-, and (S)-fexofenadine in combination with leukotriene inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120149730-A1 | METHODS AND COMPOSITIONS USING RACEMIC, (R)-, AND (S)-FEXOFENADINE IN COMBINATION WITH LEUKOTRIENE INHIBITORS | RUBIN PAUL D (US) | 2012-06-14 | — | — | US | disclosed |
| EP-1214937-B1 | Terfenadine carboxylate and the treatment of dermal irritation | SEPRACOR INC (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1707216-A1 | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors | Sepracor Inc. (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-1688142-A1 | Terfenadine carboxylate and the treatment of dermal irritation | Sepracor Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1071463-B1 | METHODS AND COMPOSITIONS USING TERFENADINE METABOLITES IN COMBINATION WITH LEUKOTRIENE INHIBITORS | SEPRACOR INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-0815860-B1 | Terfenadine carboxylate and the treatment of allergic disorders | SEPRACOR INC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20030083343-A1 | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors | SEPRACOR INC. | 2003-05-01 | — | — | US | disclosed |
| US-6509353-B1 | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors | SEPRACOR INC. | 2003-01-21 | — | — | US | disclosed |
| EP-1214937-A2 | Terfenadine carboxylate and the treatment of dermal irritation | Sepracor Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| US-6194431-B1 | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors | SUNOVION PHARMACEUTICALS INC. | 2001-02-27 | — | — | US | disclosed |
| EP-0701443-B2 | TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS | SEPRACOR INC (US) | 2000-11-22 | — | — | EP | disclosed |
| EP-0701443-B1 | TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS | SEPRACOR INC (US) | 1998-01-21 | — | — | EP | disclosed |
| EP-0815860-A2 | Terfenadine carboxylate and the treatment of allergic disorders | SEPRACOR, INC. (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0701443-A1 | TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS | SEPRACOR, INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994003170-A1 | TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS | SEPRACOR INC. (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | HRH1 1562/4885LMNA 1841/4885DRD3 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.